Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
出版年份 2019 全文链接
标题
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
作者
关键词
Hepatocellular carcinoma, Sorafenib, Metapristone, SDF-1/CXCR4, PLGA-PEG, Combination therapy
出版物
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 38, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-05-31
DOI
10.1186/s13046-019-1216-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
- (2018) Jean-Luc Raoul et al. CANCER TREATMENT REVIEWS
- Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT
- (2018) Jie Mao et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development
- (2018) Yun-Chieh Sung et al. Theranostics
- CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition
- (2017) Chuda Chittasupho et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention
- (2017) Ning Zheng et al. MOLECULAR CARCINOGENESIS
- Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma
- (2017) Junhui Sui et al. Nanoscale
- Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors
- (2017) Yunching Chen et al. Scientific Reports
- In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents
- (2016) Jichuang Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications
- (2016) Anisha A. D’souza et al. Expert Opinion on Drug Delivery
- Sorafenib with ASC-J9®synergistically suppresses the HCC progressionviaaltering the pSTAT3-CCL2/Bcl2 signals
- (2016) Junjie Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers
- (2016) Sun Di-Wen et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- ABCC2 (1249G > A) polymorphism implicates altered transport activity for sorafenib
- (2016) Danyun Wei et al. XENOBIOTICA
- Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention
- (2016) Suhong Yu et al. Scientific Reports
- Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
- (2015) Hiroshi Maeda ADVANCED DRUG DELIVERY REVIEWS
- CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer
- (2015) Dong-Yu Gao et al. BIOMATERIALS
- Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment
- (2015) Liqiong Cai et al. BIOMATERIALS
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
- (2015) Jiang Chen et al. CANCER LETTERS
- Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment
- (2015) S. Scala CLINICAL CANCER RESEARCH
- CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice
- (2015) Yunching Chen et al. HEPATOLOGY
- PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood–brain barrier
- (2015) C. Fornaguera et al. JOURNAL OF CONTROLLED RELEASE
- Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer
- (2015) Jia-Yu Liu et al. MOLECULAR THERAPY
- EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma
- (2015) Haiou Liu et al. Nature Communications
- Synthesis, Spectral Characterization, and In Vitro Cellular Activities of Metapristone, a Potential Cancer Metastatic Chemopreventive Agent Derived from Mifepristone (RU486)
- (2014) Jichuang Wang et al. AAPS Journal
- Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer
- (2014) Lei Miao et al. ADVANCED FUNCTIONAL MATERIALS
- Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles
- (2014) Chuda Chittasupho et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Hepatocellular carcinoma: clinical frontiers and perspectives
- (2014) Jordi Bruix et al. GUT
- The Unique Pharmacological Characteristics of Mifepristone (RU486): From Terminating Pregnancy to Preventing Cancer Metastasis
- (2014) Jianzhong Chen et al. MEDICINAL RESEARCH REVIEWS
- Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma
- (2013) Yingjian Liang et al. HEPATOLOGY
- αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
- (2013) Xiao-Yong Huang et al. HEPATOLOGY
- Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice
- (2013) Yunching Chen et al. HEPATOLOGY
- Small Molecule Inhibitors of CXCR4
- (2013) Bikash Debnath et al. Theranostics
- Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery
- (2011) Jianwei Guo et al. BIOMATERIALS
- Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend
- (2011) Jing Zhao et al. BIOMATERIALS
- Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
- (2011) K.-F. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- A study of drug release from homogeneous PLGA microstructures
- (2010) Ghanashyam Acharya et al. JOURNAL OF CONTROLLED RELEASE
- Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival
- (2009) Zuo-lin Xiang et al. BMC CANCER
- Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
- (2009) B. Blanchet et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More